Trial · NCT06041490
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
NCT06041490, Phase 2, Not yet recruiting, Peking Union Medical College Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation. Trials, record NCT06041490. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06041490
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
- NCT number
- NCT06041490
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 88 participants, estimated
- Lead sponsor
- Peking Union Medical College Hospital
- Conditions
- Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma, High-Risk Cancer
- Interventions
- multi-kinase inhibitors in combination with bevacizumab
- First posted
- 2023-09-18
- Last updated
- 2023-09-18
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | EFFICACY: One-year recurrence-free survival rate (1-year RFS rate) | Baseline up to 12 months | One-year recurrence-free survival rate (1-year RFS rate): The one-year recurrence-free survival rate represents the proportion of patients, within a specified study population, who remain free from disease recurrence for at least one year following a designated treatment or intervention. |
| Secondary | EFFICACY: Recurrence-free survival (RFS) duration | Baseline up to approximately 12 months | Recurrence-free survival (RFS) duration: From randomization to the time of disease recurrence evidence or any cause-induced mortality. |
| Secondary | EFFICACY: Overall survival (OS) | Baseline up to approximately 3 years | Overall survival (OS): The duration from randomization to mortality caused by any underlying factors serves as a crucial metric for evaluating the impact of interventions on study participants. |
| Secondary | EFFICACY: Two-year and three-year RFS rates | Baseline up to approximately 2-3 years | Two-year and three-year RFS rates: The two-year and three-year RFS rate represents the proportion of patients, within a specified study population, who remain free from disease recurrence for at least two or three year following a designated treatment or intervention. |
| Secondary | EFFICACY and SAFETY: Graft survival | Baseline up to approximately 3 years | Graft survival: The interval between the commencement of randomization and the occurrence of graft loss is a pivotal time frame in transplantation research. In cases where patients are unaware of graft loss or when graft loss is not documented upon patient demise without confirmed graft loss, the time of graft loss is retrospectively evaluated using either the date of the last documented contact or the date of death. |
| Secondary | QUALITY OF LIFE：Quality of life evaluation | Baseline up to approximately 3 years | Quality of life evaluation (QoL) according by FACT-Hep. |
| Secondary | SAFETY: Incidence of adverse events and serious adverse events | Baseline up to approximately 3 years | Incidence of adverse events and serious adverse events. Grade by CTCAE 5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06041490
GET https://conductscience.org/api/trials/v1/NCT06041490/registered